Affect Therapeutics Stock

Affect Therapeutics is using mobile technology to revolutionize stimulant addiction recovery.

Sign up today and learn more about Affect Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Affect Therapeutics Stock

Affect Therapeutics offers an integrated digital treatment program for drug and alcohol addiction via a mobile app. They provides treatments for a variety of substance use disorders. The program provides financial incentives to encourage healthy behaviors and new habits.

Funding History

April 2021$1.0M
July 2021$6.0M


Co-founder & Executive Chairman

Jeff De Flavio

Co-founder & Head of Product

Rachel Lin


Russell Osborne

Head Of Marketing

Natalie Pitcher Clark

Co-founder & CEO

Kristin Muhlner


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: